1 citations
,
January 2024 in “Journal of personalized medicine” Hormonal imbalances during menopause may significantly contribute to Frontal Fibrosing Alopecia.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
May 2022 in “British Journal of Dermatology” The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
1 citations
,
January 2015 in “Springer eBooks” Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.
1 citations
,
August 2007 in “Indian Journal of Pediatrics” A girl with symptoms like an autoimmune disorder actually had HIV and a fungal infection, which was hard to diagnose and treat, leading to her death.
June 2026 in “Wiener klinische Wochenschrift” New treatments for alopecia areata show promise but need ongoing use and have infection risks.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
March 2026 in “American Journal of Clinical Dermatology” Cancer survivors need better skin care to improve their quality of life.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
February 2026 in “International Journal of Dermatology” Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
January 2026 in “British Journal of Health Psychology” Alopecia affects self-confidence, body image, and social interactions, causing distress and requiring better support and awareness.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
August 2025 in “Frontiers in Immunology” Primary cicatricial alopecia is linked to various health issues, indicating broader systemic problems.
July 2025 in “Pharmaceuticals” Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
June 2025 in “Journal of Cluster Science” Metal nanoparticles show promise for treating hair loss but need more research to ensure safety.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
April 2025 in “Archives of Dermatological Research” Combining CO2 laser and Bimatoprost effectively boosts hair regrowth in Alopecia Areata.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
November 2024 in “Psychology Health & Medicine” Psychological therapies may improve quality of life for people with alopecia areata.
September 2024 in “Current Oncology” Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.